Y-mAbs Therapeutics, a biotech innovator co-founded by Danish entrepreneur Thomas Gad together with Genmab co-founder Claus Møller-San Pedro and financier Johan Wedell-Wedellsborg, has agreed to be acquired for 2.6 billion DKK (approximately $412 million USD) by SERB Pharmaceuticals, a global specialty pharma company. The transaction marks one of the most significant exits for a Danish-founded biotechnology company in recent years.
Founded in 2014 with the mission to revolutionize cancer treatment—spurred by a personal family journey through paediatric cancer—Thomas Gad brought together a team with impressive industry credentials. Claus Møller-San Pedro, well-known for his pivotal role at Genmab, and Johan Wedell-Wedellsborg, a prominent investor, were critical in building the company’s foundation and securing early-stage capital.
Y-mAbs Therapeutics became internationally recognized for its DANYELZA (naxitamab-gqgk) therapy—an innovative, FDA-approved antibody treatment for children and adults with relapsed or refractory high-risk neuroblastoma, a rare and aggressive cancer. This drug, along with the company’s advancing portfolio of antibody and radiopharmaceutical therapies, established Y-mAbs as a leader in pediatric oncology and immunotherapy.
Under the terms of the sale, announced August 5, 2025, SERB Pharmaceuticals will acquire all outstanding shares at a premium price of $8.60 per share, more than doubling the previous trading value and reflecting robust market confidence in Y-mAbs’ pipeline and commercial success. The transaction has received unanimous approval from the Y-mAbs board of directors and is expected to close by the end of 2025, pending regulatory and shareholder approvals.
Industry observers note that this acquisition underscores the growing international appetite for Danish biotech innovation, especially in specialized cancer therapies. For SERB, the deal brings a suite of cutting-edge oncology assets, strengthening their presence in rare diseases and furthering the reach of Y-mAbs’ scientific legacy.
The sale not only delivers a substantial return for its founders and investors, but also stands as a testament to the ambition and expertise generated within the Danish biotech sector—hinting at more blockbuster deals on the horizon as global pharma eyes Scandinavia for the next frontier of therapeutic breakthroughs.